TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) and Brainsway (NASDAQ:BWAY – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, analyst recommendations, institutional ownership and risk.
Risk and Volatility
TriSalus Life Sciences has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, Brainsway has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.
Earnings and Valuation
This table compares TriSalus Life Sciences and Brainsway”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TriSalus Life Sciences | $45.15 million | 5.46 | -$39.23 million | ($1.30) | -3.08 |
| Brainsway | $52.22 million | 9.19 | $7.57 million | $0.44 | 27.09 |
Brainsway has higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by insiders. Comparatively, 19.0% of Brainsway shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares TriSalus Life Sciences and Brainsway’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TriSalus Life Sciences | -62.59% | N/A | -64.47% |
| Brainsway | 15.65% | 12.74% | 8.17% |
Analyst Ratings
This is a breakdown of current ratings and target prices for TriSalus Life Sciences and Brainsway, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TriSalus Life Sciences | 1 | 1 | 3 | 0 | 2.40 |
| Brainsway | 0 | 2 | 5 | 0 | 2.71 |
TriSalus Life Sciences presently has a consensus price target of $10.20, suggesting a potential upside of 155.00%. Brainsway has a consensus price target of $18.20, suggesting a potential upside of 52.68%. Given TriSalus Life Sciences’ higher possible upside, research analysts clearly believe TriSalus Life Sciences is more favorable than Brainsway.
Summary
Brainsway beats TriSalus Life Sciences on 12 of the 13 factors compared between the two stocks.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
About Brainsway
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
